Refik Pul
Overview
Explore the profile of Refik Pul including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
97
Citations
1396
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Winter P, Axhausen F, Wolff S, Willison A, Rauber S, Konen F, et al.
J Neurol Neurosurg Psychiatry
. 2025 Mar;
PMID: 40050009
Background: The impact of body weight on disability progression rates among patients receiving ofatumumab was not evaluated yet. Methods: Among patients from a multicentre prospective cohort, baseline demographics were compared...
2.
Konen F, Mohn N, Witte T, Schefzyk M, Wiestler M, Lovric S, et al.
Autoimmun Rev
. 2025 Jan;
24(4):103754.
PMID: 39842533
A wide variety of immunomodulatory therapies are already available for the treatment of multiple sclerosis (MS). Through fundamental insights from basic research with a gain of knowledge in the pathological...
3.
Meuth S, Wolff S, Muck A, Willison A, Kleinschnitz K, Rauber S, et al.
Ann Neurol
. 2024 Nov;
97(3):583-595.
PMID: 39582359
Objective: B-cell-depletion via CD20 antibodies is a safe and effective treatment for active relapsing multiple sclerosis (RMS). Both ocrelizumab (OCR) and ofatumumab (OFA) have demonstrated efficacy in randomized controlled trials...
4.
Jendretzky K, Lezius L, Thiele T, Konen F, Huss A, Heitmann L, et al.
Neurol Res Pract
. 2024 Nov;
6(1):55.
PMID: 39533435
Background: Diagnosing multiple sclerosis (MS) is challenging due to diverse symptoms and the absence of specific biomarkers. Concurrent autoimmune diseases (AID) or non-specific antibodies further complicate diagnosis, progression monitoring, and...
5.
Schwake C, Ladopoulos T, Haussler V, Kleiter I, Ringelstein M, Aktas O, et al.
J Neurol Neurosurg Psychiatry
. 2024 Nov;
PMID: 39496464
Background: Incomplete attack remission is the main cause of disability in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD). Apheresis therapies such as plasma exchange and immunoadsorption are widely used in neuroimmunology....
6.
Kogel A, Ladopoulos T, Schwake C, Kleiter I, Teegen B, Siems N, et al.
Neurol Neuroimmunol Neuroinflamm
. 2024 Oct;
11(6):e200325.
PMID: 39393044
Background And Objectives: Cognitive impairment is a common and challenging symptom in multiple sclerosis and neuromyelitis optica spectrum disease; however, data in myelin oligodendrocyte glycoprotein-IgG-associated disease (MOGAD) remain scarce. In...
7.
Ringelstein M, Asseyer S, Lindenblatt G, Fischer K, Pul R, Skuljec J, et al.
Neurology
. 2024 Oct;
103(9):e209888.
PMID: 39353149
Background And Objectives: Attack prevention is crucial in managing neuromyelitis optica spectrum disorders (NMOSDs). Eculizumab (ECU), an inhibitor of the terminal complement cascade, was highly effective in preventing attacks in...
8.
Kowarik M, Ernst M, Woitschach L, Cepek L, Rau D, Kuhnler B, et al.
Mult Scler Relat Disord
. 2024 Jun;
88:105704.
PMID: 38878625
Background: The current approval of oral cladribine covers four years, with two treatment courses in the first two years, followed by two treatment-free years. For decision-making in year 5, experts...
9.
Pfeuffer S, Wolff S, Aslan D, Rolfes L, Korsen M, Pawlitzki M, et al.
Neurology
. 2024 Jun;
103(2):e209574.
PMID: 38870471
Background And Objectives: Relapse and MRI activity usually decline with aging but are replaced by progression independent of relapse activity (PIRA) in patients with multiple sclerosis (PwMS). However, several older...
10.
Mannherz H, Budde H, Jarkas M, Hassoun R, Malek-Chudzik N, Mazur A, et al.
Eur J Cell Biol
. 2024 Mar;
103(2):151407.
PMID: 38555846
We analyzed actin cytoskeleton alterations during NET extrusion by neutrophil-like dHL-60 cells and human neutrophils in the absence of DNase1 containing serum to avoid chromatin degradation and microfilament disassembly. NET-formation...